2003059857

03 OCT 2003

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 October 2002 (17.10.2002)

PCT

(10) International Publication Number
WO 02/081677 A3

(51) International Patent Classification[7]: C12N 15/85, 205/00, 219/00, 217/00, 15/11, 203/00

(21) International Application Number: PCT/GB02/01479

(22) International Filing Date: 5 April 2002 (05.04.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0108605.7	5 April 2001 (05.04.2001)	GB
60/281,605	5 April 2001 (05.04.2001)	US
0109335.0	17 April 2001 (17.04.2001)	GB
60/298,675	15 June 2001 (15.06.2001)	US

(71) Applicant: ML LABORATORIES PLC [GB/GB]; 17 Hanover Square, London W1S 1HU (GB).

(72) Inventors: WILLIAMS, Stephen, Geraint; Cobra Therapeutics Limited, Stephenson Building, Keele University Science Park, Keele, Staffordshire ST5 5SP (GB).

CROMBIE, Robert, Lachlan; Cobra Therapeutics Limited, Stephenson Building, Keele University Science Park, Keele, Staffordshire ST5 5SP (GB).


(74) Agents: JONES, Keith, William; Harrison Goddard Foote, Orlando House, 11c Compstall Road, Marple Bridge, Stockport SK6 5HH et al. (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent

[Continued on next page]

(54) Title: IMPROVED GENE EXPRESSION



(57) Abstract: Polynucleotides and vectors comprising an expressible nucleic acid flanked by a 5' extended methylation-free CpG island and a 3' selectable marker element are disclosed. Such polynucleotides and vectors provide a means for obtaining high levels of expression of the flanked expressible nucleic acid. Preferred embodiments include combinations of 5' extended methylation-free CpG islands and 3' antibiotic resistance genes.

WO 02/081677 A3

162162

ACTION